Clinical Trials Logo

Clinical Trial Summary

The potential participants will be informed of the study details, including the study objectives. Once they have read the study information sheet and have a good understanding of the study, those who intend to participate in the study will be asked to sign the consent form for this study. There are 2 groups of participants: MSM who seek HIV voluntary counseling and testing service (phase I) and MSM who meet nPEP criteria (phase II).


Clinical Trial Description

This study design is mixed-method, starting with quantitative research and followed by qualitative research. The study will be conducted in 2 phases: a cross-sectional study during phase I and a prospective descriptive study during phase II, which will use qualitative research techniques to help understand and define obstacles and uncover opportunities to improve adherence to post-exposure prophylaxis.

During phase I, this study is a quantitative research study using a cross-sectional study design which aims to enroll 450 men who have sex with men (MSM) within 6 months and to collect data by administration of questionnaire amongst all MSM via face-to-face interview. During phase II, we will use a quantitative research design and perform in-depth interviews with those MSM who choose to receive and choose not to receive nPEP despite the fact that they meet nPEP criteria. We expect to identify approximately 50 MSM who meet nPEP criteria during the enrollment period. The number of volunteers will be determined based on saturation theory in which the data collection will be considered complete after analysis of the data shows that additional entries provide no further information (64). The number of volunteers in phase II may not be able to be specified with certainty in advance. Enrollment of subjects will stop once data acquisition is saturated.

An initial review of demographic data and sexual behavior amongst MSM seen at the TRC-ARC will be undertaken by interviewing the TRC-ARC staff who are responsible for looking after this population. This process will aid understanding of clinic logistics and help identify opportunities to meet with MSM individuals. The potential participants will be informed of the study details, including the study objectives. Once they have read the study information sheet and have a good understanding of the study, those who intend to participate in the study will be asked to sign the consent form for this study. There are 2 groups of participants: MSM who seek HIV voluntary counseling and testing service (phase I) and MSM who meet nPEP criteria (phase II).

Phase I. MSM who seek HIV voluntary counseling and testing

1. All MSM clients will be interviewed to complete the questionnaires designed to collect information for this study before the pre-test counseling. The questions will collect demographic data and data regarding HIV risk behaviors, HIV knowledge, intention to take nPEP, factors affecting the intention to take nPEP, experience on nPEP use, and awareness of nPEP.

2. After MSM clients receive the counseling. They will be interviewed to answer the questionnaires about HIV knowledge, intention to take nPEP, factor affecting to intention to take nPEP, nPEP knowledge.

3. All MSM clients will receive pre-test counseling, HIV testing, and post-test counseling according to the standard of care at the Anonymous Clinic, TRC-ARC. Counselors will also assess clients for nPEP eligibility criteria according to the standard clinic guidelines.

Phase II. MSM who receive nPEP

1. Participant who describes a history of an HIV risk exposure within the preceding 72 hours and meets nPEP eligibility criteria as assessed by the clinic counselor. After participants receive all information to know whether they receive antiretroviral medication, they can decide by themselves about taking medication. The participant who select to take nPEP will receive a 14-day supply of nPEP medication and will be scheduled back to receive the rest of their medication.

2. Both participant who decide to take and not take nPEP will be asked to take part in the in-depth interviews to examine factors affecting the decision to use nPEP.

3. At week 6, the participants who take nPEP will be evaluated for HIV infection, adherence to medication during the 28-day course of nPEP, side effects from nPEP and asked to be interviewed about risk behaviors and other HIV prevention methods since the start of nPEP.

At each of these study visits, the participant will receive risk reduction counseling along with the provision of condoms and lubricant

In accordance to the standard of care at the Anonymous Clinic, TRC-ARC, participants who decide to take nPEP (whose risk of HIV exposure must be within the preceding 72 hours) will receive 3 antiretroviral medications; 2 nucleoside reverse transcriptase inhibitors plus 1 protease inhibitor or non-nucleoside reverse transcriptase inhibitor. The clients will receive HIV antibody testing prior to taking nPEP and at week 6 after starting nPEP. ;


Study Design

Observational Model: Case-Crossover, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT02107911
Study type Observational
Source South East Asia Research Collaboration with Hawaii
Contact
Status Completed
Phase N/A
Start date March 2014
Completion date December 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2